Sangamo Therapeutics (SGMOQ) Non-Current Assets (2010 - 2025)

Sangamo Therapeutics' Non-Current Assets history runs 16 years deep, the most recent figure standing at $23.9 million for Q4 2025.

• On a quarterly basis, Non-Current Assets fell 52.12% year-over-year to $23.9 million in Q4 2025; TTM through Dec 2025 was $164.7 million, a 23.86% decrease from a year earlier, with the FY2025 full-year figure at $23.9 million, down 52.12% from the prior year.
• Non-Current Assets retreated to $23.9 million in Q4 2025 per SGMOQ's latest filing, from $44.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $325.0 million in Q3 2021 and bottomed at $23.9 million in Q4 2025.
• The 5-year median for Non-Current Assets is $118.8 million (2023), against an average of $160.5 million.
• Across the five-year window, Non-Current Assets surged 30.68% in 2021 and sank 72.92% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $323.2 million in 2021, then declined by 18.87% to $262.2 million in 2022, then sank by 72.92% to $71.0 million in 2023, then fell by 29.65% to $49.9 million in 2024, then tumbled by 52.12% to $23.9 million in 2025.
• Per Business Quant, the three latest SGMOQ Non-Current Assets figures stand at $23.9 million (Q4 2025), $44.6 million (Q3 2025), and $47.7 million (Q2 2025).